用传统的放射性磷或烷基化药物治疗真性红细胞增多症(PV)伴发急性白血病和胃肠道及皮肤癌的机会较多。羟基脲(HU)是核糖核甙还原酶的抑制剂,是一种非烷基化骨髓抑制药,迄今未确示其能致白血病。过去用过骨髓抑制治疗后者最少等4月才用HU。为了仅用小量补充放血能达到和维持红细胞比积<50和血小板<100万,开始1周用HU30mg/kg/日,以后用15mg/kg/日,如白细胞减少则减量,如红细胞比积控制不理想则增量5mg/kg/日,补充的放血术(300-500ml)每年少于6次。将病人分为初期反应和长期控制评定。开始有红细胞比积增高未接受早期 There is a good chance of treating polycythemia vera (PV) with acute leukemia and gastrointestinal and skin cancer with traditional radioactive phosphorus or alkylating drugs. Hydroxyurea (HU), an inhibitor of ribonucleoside reductase, is a non-alkylated bone marrow suppressant that has not been shown to cause leukemia. In the past, the latter had been treated with myelosuppression for at least 4 months with HU. In order to reach and maintain hematocrit <50 and platelet <1 million with only a small amount of supplementary bloodletting, HU30mg / kg / day for the first week, 15mg / kg / day for the later, leucopenia, Product control is not ideal increment 5mg / kg / day, supplementary bleeding (300-500ml) less than 6 times per year. Patients were divided into initial response and long-term control assessment. The beginning of the increase in hematocrit was not accepted early